Hemostasis Today

October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Abdul Mannan: PCC vs. aPCC – The Small ‘a’ That Changes Emergency Management
Oct 12, 2026, 07:28

Abdul Mannan: PCC vs. aPCC – The Small ‘a’ That Changes Emergency Management

Abdul Mannan, Consultant Haematologist, Director Haemophilia Centre, Haematology Lab Lead at Betsi Cadwaladr University Health Board, shared a post LinkedIn:

“That small ‘a’ changes the bleeding treatment you choose.

PCC and aPCC have similar names, but different jobs.

Their dosing units are not equivalent.

For trainees, start with the mechanism:

  • 4-factor PCC replaces factors II, VII, IX and X, predominantly in their non-activated forms.

Think urgent warfarin reversal, with intravenous vitamin K. Beriplex and Octaplex also contain proteins C and S, plus heparin.

  • Activated PCC (aPCC), such as FEIBA, contains mainly non-activated factors II, IX and X, plus activated FVII.

It supports thrombin generation despite FVIII or FIX inhibitors.

  • Monitoring differs. Follow INR and clinical response after PCC for warfarin reversal. With FEIBA, assess bleeding clinically: aPTT correction does not reliably predict haemostatic efficacy.

Before choosing a bypassing agent, check whether the patient receives emicizumab.

Combining emicizumab with aPCC can cause thrombosis and thrombotic microangiopathy. For haemophilia A with inhibitors on emicizumab, WFH guidance prefers recombinant activated factor VII (rFVIIa) when bypassing treatment is needed.

PCC and aPCC are not interchangeable.

Check the product, indication and haemophilia centre plan before treatment.

Which part of this distinction causes the most confusion on call?”

Abdul Mannan

More posts featuring Abdul Mannan on Hemostasis Today.